The pressuresthat matter are the hardest to measure.
Coredio is building a way to estimate pressures inside the heart without a catheter, so heart failure care is not limited to what a scale and a symptom check can show.
Our story
It started as a research problem.
The company holds an exclusive patent license from RIT and has been developing the
Cardiac Performance Simulation Engine since 2023.
Coredio grew out of cardiovascular simulation research at Rochester Institute of Technology,
where the founding work focused on treating the circulation as a physical system instead of looking for patterns in population data.
Founded
2023
Based
Mountain View, CA
Technology
Licensed from RIT
V1 of the algorithm
2024
First clinical data
2025
FDA
Breakthrough, March 2026
Program
FDA TAP
Team
Who is building it.
Chief Executive Officer
Yashar Seyed Vahedein
Ph.D.
Chief Technology Officer
Mehdi Mortazawy
Tech development
Chief Medical Officer
Jennifer Monti
M.D.
Our clinical advisors
Clinicians and hospital partners who advise us on workflow, validation and clinical fit.
Youssef Rahban
MD, FACC
Judah Rauch
Interventional cardiologist
Farrukh Jafri
ER doctor and RPM expert
Saba Lahsaei
Interventional cardiologist
Tara Lagu
Alliant Health Solutions
Ioannis Mastoris
MGH
Anjan Tibrewala
Cardiologist
How we work
Three things we hold ourselves to.
From cardiac data to clinical insight
Coredio’s AI transforms multimodal cardiac data into intelligent reports, helping clinicians understand patient-specific hemodynamics and trends with greater clarity.
Where we are
It is early, and we say so.
Investigational
Not cleared or approved. Breakthrough Designation is a review pathway, not a finding of safety or effectiveness.
In validation
Early work against catheterization data with hospital partners. Results are not yet published.
No outcome claims
We have not demonstrated readmission reduction and do not claim it.
Pre-
commercialSite engagements are research and evaluation only.
Frequently asked questions
A compatible smartwatch and a blood pressure cuff. If you do not already have a watch, we provide one as part of the home setup.
Connect with the Coredio team
Join the clinicians exploring a better way to monitor heart failure
FDA | Disclaimer:
Coredio CPSE™ has received FDA Breakthrough Device Designation. The device is not yet cleared by the FDA for commercial use. Indications for Use are subject to FDA review under the 510(k) process.